- Home
- FGF vs ENLV Comparison
FGF vs ENLV Comparison
Compare FGF & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- ENLV
- Stock Information
- Founded
- FGF 2012
- ENLV 2005
- Country
- FGF United States
- ENLV Israel
- Employees
- FGF N/A
- ENLV N/A
- Industry
- FGF Property-Casualty Insurers
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- ENLV Health Care
- Exchange
- FGF Nasdaq
- ENLV Nasdaq
- Market Cap
- FGF 20.2M
- ENLV 20.7M
- IPO Year
- FGF N/A
- ENLV 1995
- Fundamental
- Price
- FGF $17.20
- ENLV $1.02
- Analyst Decision
- FGF
- ENLV Strong Buy
- Analyst Count
- FGF 0
- ENLV 2
- Target Price
- FGF N/A
- ENLV $10.00
- AVG Volume (30 Days)
- FGF 1.2K
- ENLV 51.8K
- Earning Date
- FGF 05-19-2025
- ENLV 06-13-2025
- Dividend Yield
- FGF N/A
- ENLV N/A
- EPS Growth
- FGF N/A
- ENLV N/A
- EPS
- FGF N/A
- ENLV N/A
- Revenue
- FGF $17,348,000.00
- ENLV N/A
- Revenue This Year
- FGF N/A
- ENLV N/A
- Revenue Next Year
- FGF N/A
- ENLV N/A
- P/E Ratio
- FGF N/A
- ENLV N/A
- Revenue Growth
- FGF 1.49
- ENLV N/A
- 52 Week Low
- FGF $14.21
- ENLV $0.81
- 52 Week High
- FGF $38.40
- ENLV $1.76
- Technical
- Relative Strength Index (RSI)
- FGF 53.40
- ENLV 52.42
- Support Level
- FGF $16.27
- ENLV $1.03
- Resistance Level
- FGF $17.27
- ENLV $1.15
- Average True Range (ATR)
- FGF 0.30
- ENLV 0.06
- MACD
- FGF 0.20
- ENLV 0.01
- Stochastic Oscillator
- FGF 96.05
- ENLV 53.07
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segments includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.